Effect of apalutamide dosage on the incidence of cutaneous adverse events and prostate‑specific antigen reduction in patients with prostate cancer
Takuya Matsuyam, Michio Kimura, Makiko Go, Shiori Yamada et autres
1 citationOncology Letters
Shiori Yamada
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
13Publications signalées
13Citations signalées
1Affiliations récentes
Institutions déclarées
Domaines associés
Hepatocellular Carcinoma Treatment and PrognosisCancer-related Molecular PathwaysHER2/EGFR in Cancer ResearchAdvanced Breast Cancer TherapiesOvarian cancer diagnosis and treatment
Publications récentes
Development and Validation of Protocol-Based Pharmacotherapy Pharmacist Outpatient Clinic for Patients Receiving Oral Anticancer Monotherapy
Makiko Go, Michio Kimura, Shiori Yamada, Mitsuhiro Nishimura et autres
0 citationsIryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)
Exploratory Study on the Efficacy and Safety of Mirogabalin and Duloxetine for Chemotherapy-Induced Peripheral Neuropathy
Takuya Matsuyama, Michio Kimura, Makiko Go, Shiori Yamada et autres
0 citationsIryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)
Safety and Treatment Continuity of Switching between CDK4/6 Inhibitors for Metastatic Breast Cancer due to Adverse Events: An Exploratory Single-Center Study in Japan
Makiko Go, M Kimura, Shiori Yamada, Keitaro Kamei et autres
0 citationsOncology
Factors Influencing Severe Hematologic Toxicity Following Niraparib Therapy in Patients With Ovarian Cancer
Michio Kimura, Shiori Yamada, Rina Matsuyama, Makiko Go et autres
1 citationCancer Diagnosis & Prognosis
Alternative Palbociclib Dosing Schedules for Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer
Makiko Go, M Kimura, Shiori Yamada, Keitaro Kamei et autres
0 citationsOncology
Evaluation of Tolerability of Niraparib in Older Patients with Ovarian Cancer
Rina Takahashi-Matsuyama, Takuya Matsuyama, Hiroshi Murase, Mitsuhiro Nishimura et autres
0 citationsIryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)
Identifying risk factors of dose reduction or treatment discontinuation due to fatigue or gastrointestinal symptoms in patients receiving lenvatinib treatment for hepatocellular carcinoma
Michio Kimura, Shiori Yamada, Makiko Go, Satoshi Yasuda et autres
0 citationsJournal of Oncology Pharmacy Practice
Safety evaluation of lenvatinib treatment after atezolizumab plus bevacizumab therapy for patients with unresectable liver cancer: A comparison of lenvatinib as 1st‑ or 2nd‑line treatment
Michio Kimura, Shiori Yamada, Makiko Go, Satoshi Yasuda et autres
4 citationsOncology Letters
Comparison of Safety and Treatment Continuity of Palbociclib and Abemaciclib for Hormone Receptor-Positive, HER2-Negative Metastatic/Recurrent Breast Cancer
Makiko Go, M Kimura, Shiori Yamada, Eiseki Usami et autres
2 citationsJournal of Pharmacy Practice
Evaluation of Atezolizumab Plus Bevacizumab Versus Modified Lenvatinib Therapy in Child-Pugh A Unresectable Hepatocellular Carcinoma
Michio Kimura, Shiori Yamada, Makiko Go, Satoshi Yasuda et autres
0 citationsCancer Diagnosis & Prognosis
Evaluation of the therapeutic effects and tolerability of modified lenvatinib administration methods for unresectable hepatocellular carcinoma: A preliminary study
Michio Kimura, Makiko Go, Shiori Yamada, Hiroki Asano et autres
4 citationsOncology Letters
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.